• Sep 2007-Oct 2012 Ph.D. in Pharmaceutical Science, Ernest Mario School of Pharmacy, Rutgers University, New Jersey, U.S.A.
  • Advisor: Ah-Ng Tony Kong, Ph.D.
    • Cell-based drug development for cancer chemoprevention studies
    • Designed and implemented pharmacokinetic (PK) and pharmacokinetic/ pharmacodynamic (PK/PD) and pharmacogenomics studies to determine the absorption, distribution, metabolism, elimination (ADME) of new drug candidates
    • WinNonlin, NONMEN, ADAPT software for PK studies
• Sep 1999-June 2003 Bachelor of Science in Pharmacy, School of Pharmacy, Taipei Medical University, Taipei City, TAIWAN
• August 2013-May 2014 Postdoctoral Fellow (Advisor: Dr. Leroy F. Liu), Taipei Medical University, Taipei City, TAIWAN
  • Antiaging and mitochondrial function restored by phytochemicals
• Jan 2013-August 2013 Postdoctoral Fellow (Advisor: Dr. Xiajun Li), Mount Sinai Medical Center, New York, NY, U.S.A.
  • Genomic imprinting and stem cell reprogramming (referred Publication #17)
• Oct 2012-Jan 2013 Postdoctoral Associate (Advisor: Dr. Ah-Ng Tony Kong), Rutgers University, New Jersey, U.S.A.
• May 2011-Oct 2011 Research Associate, Translational Science, DMPK-Clinical PK/PD, Novartis Institute for Biomedical Research, Novartis Pharmaceutical Corporation, East Hanover, NJ, U.S.A.

• August 2022- Associate Professor, Graduate Institute of Clinical Pharmacy, Tzu Chi University
• March 2015-August 2022 Associate/ Assistant Professor, Dept. Pharmacology, School of Medicine, Tzu Chi University
  • High teaching quality with average 4.5/5.0
  • English-as-medium-of-instruction (EMI) courses: Research Techniques in Pharmacology and Toxicology (TCU), Advanced Biotechnology (TCU), Advanced Pharmacology (TCU), Current Topics in Pharmacology and Toxicology (TCU), Special topics in translational medicine of Chinese herbal medicine (TMU) and Clinical drug discovery of pharmacokinetics & pharmacodynamics from botanical herbs (TMU)
  • Graduate program teaching courses: Pharmacogenomics and Clinical Application (TCU), Clinical Pharmacokinetics and Blood Concentration Monitoring (TCU)
  • PBL tutor for medical classes (6 years)
• Sep 2007- June 2012 Teaching Assistant at Dept. of Clinical Pharmacy Practice and Dept. of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, NJ, U.S.A. 
  • Teaching PharmD class and recitation in Biopharmaceutics and Pharmacokinetics (PK)
  • Teaching PharmD classes in Pharmacy Compounding Lab and Pharmacy Practice Lab
  • Mentoring Pharm.D. students in Pharmacy Honor Program for research
• May 2006- July 2007 Clinical Pharmacist II, Buddhist Tzu-Chi General Hospital, Taipei Branch, New Taipei City, TAIWAN
  • Instructed students in pharmacy internship
• May 2005- Apr 2006 Registered Pharmacist, China Medical University Hospital, Taichung City, TAIWAN
  • Instructed students in pharmacy internship

• Clinical Pharmacogenomics Research
• Clinical Pharmacokinetics, Pharmacodynamics and Drug Metabolism
• Pharmacokinetics Pharmacodynamics Modeling and Simulations
• Drug utilization research

• Oct 2022 Distinguished Research Award of Tzu Chi Medical Foundation 慈濟醫療法人年度最佳研究獎
• Oct 2020 Distinguished Research Award of Tzu Chi Medical Foundation 慈濟醫療法人年度最佳研究獎
• Nov 2019 Distinguished Mentor Award of TCU 慈濟大學校級優良導師
• Dec 2017 Distinguished Teaching Award of School of Medicine, TCU 慈濟大學醫學系教學優良教師
• May 2012 Gallo Award for Scientific Excellence, The 2012 Annual Retreat on Cancer Research in New Jersey
• Oct 2011 2011 AAPS Graduate Student Symposium Award in Pharmacokinetics, Pharmacodynamics, Drug Metabolism and Clinical Pharmacology and Translational Research
• Oct 2011 Conference Travel award, Graduate School-New Brunswick, Rutgers, NJ, U.S.A.
• Apr 2011 Rutgers Competitiveness Pool Founds award, Rutgers, NJ, U.S.A.
• Oct 2010 Conference Travel award, Graduate School-New Brunswick, Rutgers, NJ, U.S.A.
• Apr 2009 Rutgers Competitiveness Pool Founds award, Rutgers, NJ, U.S 

Professional Service

• 2025- Committee member, Clinical Trail Review Committee (IRB), Taipei Tzu Chi Hospital, Taipei City, TAIWAN
• 2024- 財團法人醫藥品查驗中心 (CDE)  新藥審查 (PK) 諮詢委員
• 2023- 台灣臨床藥學會教育發展委員會委員
• 2021- 台灣藥物基因體學會理事
• 2018- 台灣臨床藥學會繼續教育/師資培育繼續教育審查委員
• 2016- Executive Secretary and Committee member, Research Ethics Committee (IRB), Taichung Tzu Chi Hospital, Taichung City, TAIWAN

Professional Certification

• Certification of Pharmacist, TAIWAN 藥字第030343號
• Certification of Hospital Pharmacy Practice Level 4, Taiwan Society of Health-System Pharmacists (TSHP) P4-041 台灣臨床藥學會認證P4藥師 P4-041號

Journal Reviewer

• Cells
• International Journal of Molecular Science (IJMS)
• International Journal of Clinical Pharmacy
• Journal of Food and Drug Analysis (JFDA)
• Current Pharmacology Reports
• Drug & Therapy Perspectives
• The Open COVID Journal-BMS

Other Professional Experience

• August 2022 – July 2023 Associate Professor, Graduate Institute of Clinical Pharmacy, Tzu Chi University, Hualien, TAIWAN
• March 2015 – July 2023 Pharmacy Research Consultant, Department of Pharmacy, Taichung Tzu Chi Hospital, Taichung City, TAIWAN
• June 2016- July 2023 Executive Secretary, Research Ethics Committee (IRB), Taichung Tzu Chi Hospital, Taichung City, TAIWAN
• January 2018- July 2023 Executive Secretary, Taichung Tzu Chi BioBank Ethical, Governing Committee (EGC), Taichung Tzu Chi Hospital, Taichung City, TAIWAN
• August 2019- August 2020 Director, Center for Precision Instrument and Core Facility, Office of Research and Development, Tzu Chi University, Hualien, TAIWAN
• May 2014- July 2015 Section Chief, Pharmaceutical Research, Department of Pharmacy, Taichung Tzu Chi Hospital, Taichung City, TAIWAN.
  • Clinical pharmacology and PK development
  • Preceptor, Pharmacy PGY trainee, and Pharmacy student
  • 藥師PGY教學補助計畫負責人
• May 2006- July 2007  Pharmacist Level II, Buddhist Tzu-Chi General Hospital, Taipei Branch, Taipei
• May 2005- Apr 2006 Registered Pharmacist, China Medical University Hospital, Taichung City, TAIWAN

Research Project

PI Project

• NSTC 111-2320-B-320-005 The active constituents of Polygonum multiflorum and its synthesis derivatives in the chemoprevention and precision health on the prostate cells
• TTCRD 112-28 Changes and possible mechanisms of peptic ulcer disease medications affecting type 2 diabetes mellitus-related genes
• TTCRD 111-31 The possible mechanism of type 2 diabetes mellitus caused by clinical medication-phenytoin.
• TTCRD 110-28 Development of PPARs modulators against insulin resistance
• TCMRC-P-109007 Antioxidative stress of THSG in the prostate cell
• TTCRD 109-25 Safety assessment of common health food - Effects on cytochrome P450s
• MOST 108-2314-B-320-003 The protective effect and mechanism of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (THSG) in hearing damage research
• MOST 106-2320-B-320-003 The pharmacokinetics, pharmacodynamics, and mechanism of natural phytochemicals in the cancer microenvironment
• MOST 105-2320-B-320-001 Mechanism of Tanshinones as cancer chemopreventive agents induced pharmacogenomics and epigenetics modification in colorectal cancer
• TTCRD 108-24 The Metabolism Pathway and Drug-Drug Interactions Study of THSG
• TCMRC-P-107015 Pharmacodynamic Model of 2,3,5,4'-tetrahydroxystilbene-2-O-beta- D-glucoside (THSG) on Cancer Chemoprevention
• TTCRD105-16 Mechanism of Nrf2-related epigenetic modification stimulated by herbal crude extract

Co-PI Project

• MOST 110-2221-E-320 -001 -MY3 多巴胺受體複合G蛋白或抑制蛋白的分子活化機制與內部訊息傳遞路徑之分子模擬研究
• MOST 110-2320-B-033 -002 探討台灣小果柑橘果渣之癌症化學預防功效與表觀遺傳作用機制
• TTCRD109-26 Benefits Analysis of Pharmacists Intervention Multi-drug Integration in Chronic Patients by Outpatient Pharmaceutical Care Model：A retrospective cohort study
• TTCRD108-23台灣民間傳統草藥驗方考究及探討
• TTCRD108-22 Retrospective cohort study of the drugs’ association hospitalized patients' fall risk analysis using the Medication Fall Risk Score (MFRS)
• TCMF-SP-108-04 Role of Inflammation Mechanism in Pathogenesis of Alzheimer’s Disease- Preclinical identification of biomarkers and development of novel therapeutic compound
• TCMF-MP 108-01-01 The Cochlear implantation and auditory care medicine
• TTCRD107-21 The pharmaceutical care on enhanced DM patient medication compliance, quality of life, and improved prognosis
• TTCRD107-22 Establish the model of Pharmacist's intervention in post-acute care
• TTCRD106-19 Establish Computerized Clinical Drug Safety Models- Analysis of Risk in Therapeutic Drug Monitor
• TTCRD104-21 Establishing Continuous Pharmaceutical Serices for High-Alert Medications
• TTCRD104-22 Establish a continuous family pharmaceutical care system for patients with an adverse skin reaction to targeted cancer therapy
• TTCRD103-31 The Emerging Concept in the 21st century: To set up a seamless cancer care system of family pharmacist